Windward Bio has secured $200M in Series A financing to launch its clinical-stage drug development focused on long-acting treatments for severe respiratory conditions, including asthma and COPD.
Company Information
Company
Windward Bio
Location
Basel, Basel City, Switzerland
About
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Windward Bio ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BaselBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma